7 / 17
Page 35
Notes:
Journal of Clinical and Experimental Toxicology | Volume: 03 | ISSN: 2630-4570
allied
academies
November 04-05, 2019 | Prague, Czech Republic
2
nd
World Congress on
TOXICOLOGY AND APPLIED PHARMACOLOGY
Characterization and evaluation of the GG polymer to regulate intestinal motility in
Hemiparkinsonism rat model
Ehekatzin García Valdés
Instituto Politécnico Nacional, México
P
arkinson's disease (PD) is usually characterized by
cardinal motor impairments. However, a range of non-
motor symptoms precede the motor-phase and are major
determinants for the quality of life. To date, no disease
modifying treatment is available for PD patients. The
gold standard therapy of levodopa is based on restoring
dopaminergic neurotransmission, thereby alleviating
motor symptoms, whereas non-motor symptoms remain
undertreated. Constipation is a problem that affects
approximately 50-70% of people with Parkinson's disease
(PD) due to alterations in the autonomic nervous system
(ANS), which regulates involuntary movements of the
digestive tract. In this regard, it has been reported that
the administration of soluble and insoluble fiber improves
the symptoms of idiopathic chronic constipation. Guar
gum (GG) is a polymer of relatively recent use, derived
from the seeds of the Cyamopsis tetragonoloba plant
from the Leguminosae family. GG has proven to be
effective in softening and improving faecal production and
increasing the capacity of faeces load and sensation of
faecal excretion. Amaranth grain (AG) has unique protein
content. Due its composition, amaranth protein resembles
the one found in milk products and it is very close to the
ideal protein characteristics proposed by the Food and
Agriculture Organization (FAO) for human consumption.
The purpose of this paper is to propose a product which
chemical properties will contribute to increase the
peristalsis.
Biography
Ehekatzin García Valdés is a biotechnology engineer, currently studying
the master´s degree in Advance Technology at the Instituto Politécnico
Nacional in a collaboration with Univesidad Nacional Autónoma de
Mexico, where he is developing an alternative for the treatment of
chronic constipation suffered by patients with Parkinson´s disease.
He has experience in the development of functional foods, protein
extraction and physical characterization.
e:
09ehekatzin94@gmail.comEhekatzin García Valdés, J Clin Exp Tox, Volume: 03
DOI: 10.35841/2630-4570-C2-009